Nancy Navarro-Gonzalez, MD
Psychiatry · Miami, FLNPI 1932125275
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,223 of the $5,190 with a category attached, or 81.4%. 20 manufacturers reported payments, led by AbbVie at 24.4% of the total.
Across 246 payments — averaging $21.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- E.r. Squibb & Sons, L.L.C.$1K
- Sunovion Pharmaceuticals Inc.$763
- Takeda Pharmaceuticals U.S.A., Inc.$412
- Otsuka America Pharmaceutical, Inc.$362
- Teva Pharmaceuticals USA, Inc.$251
- plus $911 from 14 others
Across 504 payments — averaging $5137.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$1.2M
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$962K
- Boehringer Ingelheim$394K
- Teva Pharmaceuticals USA, Inc.$52K
- Boehringer Ingelheim RCV GmbH & Co KG$13K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$9K
- plus $167 from 1 others
What the payments were for
- Travel & lodging$85616%
- Food & beverage$4,22381%
- Education$1112%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 93 | $1,265 |
| E.r. Squibb & Sons, L.L.C. | 10 | $1,225 |
| Sunovion Pharmaceuticals Inc. | 47 | $763 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $412 |
| Otsuka America Pharmaceutical, Inc. | 22 | $362 |
| Teva Pharmaceuticals USA, Inc. | 9 | $251 |
| Alkermes, Inc. | 9 | $181 |
| Lundbeck LLC | 11 | $181 |
| Genentech USA, Inc. | 2 | $107 |
| Neuronetics, Inc. | 3 | $86 |
| Shire North American Group Inc | 4 | $79 |
| Bausch Health US, LLC | 3 | $52 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $50 |
| Vanda Pharmaceuticals Inc. | 2 | $48 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Lilly USA, LLC | 1 | $21 |
| Abbott | 1 | $21 |
| Viiv Healthcare Company | 1 | $20 |
| Johnson & Johnson | 1 | $16 |
| Eisai Inc. | 1 | $16 |
How this compares
$5,190 in reported general payments places this provider in the 85th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NamzaricMemantine Hcl/Donepezil Hcl | 17 | $21,032 |
| Vilazodone Hcl | 31 | $3,450 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 22 | $2,983 |
| Clonazepam | 110 | $1,339 |
| Bupropion XlBupropion Hcl | 46 | $1,137 |
| Quetiapine Fumarate | 72 | $1,071 |
| Alprazolam | 111 | $970 |
| Memantine Hcl | 32 | $861 |
| Aripiprazole | 30 | $754 |
| Temazepam | 79 | $504 |
| Lorazepam | 86 | $493 |
| Hydroxyzine Hcl | 21 | $441 |
| Buspirone Hcl | 55 | $435 |
| Zolpidem Tartrate | 49 | $407 |
| Duloxetine Hcl | 22 | $377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieNamzaric | $1,265 | $21,03217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Miami
- Kenny PerezMiami$453K
- Erik CabreraMiami$357K
- Miguel FloresMiami$176K
- Pedro RodriguezMiami$96K
- John NewcomerMiami$96K
- Patricia JunqueraMiami$80K
- Marc AgroninMiami$66K
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.